in the antiavoidance, catalepsy and ptosis tests was investigated in mice for the purpose of predicting the extrapyramidal side-effects of neuroleptics. The cataleptic effect of most neuroleptics used was antagonized to some extent by biperiden, while the ptotic effect was hardly influenced. The antiavoidance effect of neuroleptics was differen tially antagonized by biperiden. The antiavoidance effect of haloperidol, trifluperidol and perphenazine was markedly antagonized and that of chlorpromazine moderately.
However, the effect of thioridazine, chlorprothixene, levomepromazine and clozapine was little antagonized.
In neuropharmacological tests, haloperidol, trifluperidol and perphenazine exhibited a selective antidopaminergic activity, while chlorprothixene, levomepromazine and clozapine showed antidopaminergic, antiadrenergic and also anticholinergic activities when similar doses were given. These results indicate that biperiden antagonism may be marked in the tests related to the extrapyramidal symp toms and in drugs liable to induce extrapyramidal side-effects, however, there would be little or no antagonism in drugs possessing the anticholinergic property and eliciting few extrapyramidal side-effects Extrapyramidal symptoms often arise during psychiatric therapy with neuroleptics.
When evaluating new neuroleptics, investigators try to predict the extent of such side-effects as well as the antipsychotic efficacy. The extrapyramidal side-effects have been evaluated by comparing relative effects of each neuroleptic in various pharmacological tests. Among various tests, catalepsy has been regarded as an animal model capable of predicting extra pyramidal symptoms (1) (2) (3) (4) (5) . Some investigators (5-7) suggested the correlation of rotational or stereotyped behavior with such symptoms. Thus, drugs with weak activities in these tests may be considered as having a low incidence of extrapyramidal side-effects. In addition, Janssen and van Bever (8) proposed that the relative potencies of neuroleptics in the jumping box test and the apomorphine antagonism test might serve as a useful measure of such side effects. Although the conclusions derived from these methods often correspond to the virtual incidence of side effects, such is not evident in all cases.
The present study was undertaken to design another method for predicting the potency of extrapyramidal side-effects of neuroleptics. Anticholinergics, which have been used in the therapy of extrapyramidal symptoms, were reported to antagonize differentially various pharmacological effects of the neuroleptic in animal tests (2, 5) . We attempted to determine whether or not there was any difference also among neuroleptics regarding the degree of Antiavoidance test: The apparatus and procedure used were as described in a previous paper (9) . In short, the mice were trained in a box with two compartments, one darkened and the other not. Each trial was started by placing a mouse in the darkened compartment and then a click sound stimulus was given for 5 sec. Unless a mouse moved into the other compartment within 5 sec of the sound stimulus, an electric shock (5 mA, 50 Hz, 10 m sec) was delivered to the feet for 5 sec. When the mouse reached the other compartment within the first 5 sec, such action was counted as an avoidance response. The mouse was manually returned to the darkened compartment and the next trial was started.
Most of mice acquired the avoidance response for 40-50 trials of training. The animals that showed evidence of the avoidance rate (% of avoidance responses in 10 trials) more than 80 % were used for the studies, in groups of 10. For each treatment, a dose-response curve was constructed and ED50, the dose required to reduce the avoidance rate to 50% was calculated.
Catalepsy and ptosis tests: At the appropriate time after administration of neuroleptics, a group of 10 mice was tested for catalepsy according to the method of Ueki et al. (10) with modification, and then for ptosis according to the method of Irwin (11) .
In the catalepsy test, each mouse was placed with hindpaws on a flat surface and forepaws on a parallel bar 4.5 cm above the surface. The mice which failed to remove their paws from the bar within 30 sec were considered to be cataleptic. The percentage of cataleptic mice in each group was used to construct the dose-response curve and to calculate the dose which produced catalepsy in 50 % of the mice tested (ED50).
In the ptosis test, the degree of palpebral closure was expressed with scoring (score 0: . The mean score for each group was used to construct the dose-response curve from which the dose required to reduce the mean score to 50 % (ED50) was calculated.
Anti-apororphine and anti-noradrenaline tests: The comparative potency of the antidopaminergic and antiadrenergic activities of neuroleptics was determined by the anti apomorphine (12) and anti-noradrenaline (13) tests on a group of 10 mice, respectively.
Injection of apornorphine (1 mg/kg s.c.) to mice elicited continuous verticalization , and such is considered to be associated with the stimulation of dopamine receptors in the neostriatum (12) . Then the suppression of this stereotyped behavior was used as an index of antidopaminergic activity. At the appropriate time after administration of test drugs, apomorphine was injected s.c. and 20 min thereafter animals were observed for about 1 min.
The degree of verticalization was scored (0-4) for each treatment and the dose required to reduce the mean score to 50% (ED50) was calculated. Antagonism of the mortality by noradrenaline (1 mg/kg i.v.) was used as an index of the antiadrenergic activity. After the same treatment of test drugs as in the anti-apomorphine test, noradrenaline was given i.v.
and survival after 24 hr was used as the criterion for the drug effect. The dosage required for 50 % of mice to survive (ED50) was calculated.
Mydriasis and anti-oxotremorine tests: The anticholinergic activity of neuroleptics was determined by the mydriasis and anti-oxotremorine tests (14) on groups of 5 mice, respectively. In the mydriasis test, the pupil size was measured using a stereoscopic micro scope. Then, the dose which dilated the pupil size to twice that of the control group (ED 200%) was estimated. In the anti-oxotremorine test, mice were injected with oxotremorine The cataleptic effect of most neuroleptics used was reduced to some extent, by biperiden 10 mg/kg p.o. (Fig. 3) . The cataleptic effect of haloperidol, trifluperidol, perphenazine and thioridazine was markedly reduced and the dose-response curves were considerably shifted to the right. The ED50 values of haloperidol, trifluperidol, perphenazine and thioridazine, alone, were 0.64 (0.38-1.08), 0.14 (0.07-0. 30 higher doses and the effect of chlorprothixene and levomepromazine at some doses were also reduced by biperiden.
The ptotic effect of all neuroleptics tested was little reduced by biperiden 10 mg/kg p.o.
and the dose-response curves changed little (Fig. 4) In these experiments, it was found that there was some difference among tests and also among neuroleptics regarding the degree of antagonism by biperiden. 
Neuropharmacological activities of neuroleptics
Neuropharmacological activities of neuroleptics were examined to attain a better comprehension of the differential antagonism of their effects by biperiden. Effects of neuroleptics in the anti-apomorphine and anti-noradrenaline tests are shown in Table 1; these tests are considered to be appropriate for evaluating antidopaminergic and anti adrenergic activities. Haloperidol, trifluperidol and perphenazine suppressed the verti calization induced by apomorphine (1 mg/kg s.c.) in relatively low doses, but much higher doses were required to protect mice against a lethal dose of noradrenaline (1 mg/kg i.v.).
The ratios of anti-noradrenaline to anti-apomorphine effect of haloperidol, trifluperidol and perphenazine, as compared by each ED50 value, were 63.7, 56.7 and 33.7, respectively.
On the other hand, the anti-apomorphine effects of chlorpromazine, thioridazine, chlor prothixene, levomepromazine and clozapine were seen at almost the same or slightly higher doses as compared with the anti-noradrenaline effect and the ratios of anti-noradrenaline ED50 to anti-apomorphine ED50 of the drugs were nearly 1. It was confirmed that pimozide and spiroperidol (neuroleptics having the property of a typical dopamine blocker) showed a selective anti-apomorphine effect, while phentolamine and phenoxybenzamine (a-blockers)
showed a selective anti-noradrenaline effect. The effects of neuroleptics in the mydriasis and anti-oxotremorine tests were also examined as indexes of the anticholinergic activity and results are shown in Table 2 . Among the neuroleptics tested, chlorprothixene, levomepromazine and clozapine induced mydriasis and also suppressed the tremor induced by oxotremorine (0.5 mg/kg i.p.). Thioridazine and chlorpromazine had a moderate anti-oxotremorine effect, but failed to induce a mydriatic effect. Haloperidol, trifluperidol and perphenazine showed little effect in either test.
Biperiden and trihexyphenidyl (anticholinergics) proved to have potent activities in both tests.
In these neuropharmacological tests, a selective antidopaminergic activity was seen in drugs with potent cataleptic and antiavoidance effects which were markedly antagonized by biperiden. On the other hand, drugs in which biperiden antagonism was little or absent, had anticholinergic properties.
DISCUSSION
The present study was an attempt to predict the extrapyramidal side-effects of neuroleptics by comparing the degree of interaction between an anticholinergic, biperiden, and various neuroleptics. It was found that there was some difference in such interactions, perhaps reflecting the correlation with extrapyramidal side-effects.
There is an extensive literature on the antagonism of the effects of neuroleptics by anticholinergic drugs in various pharmacological tests (1, 2, 5, 6, 16-27). Morpurgo and
Theobald (2) reported that anticholinergics, scopolamine and trihexyphenidyl, were capable of reducing the effects of three phenothiazines in such tests as catalepsy, locomotion, am phetamine toxicity, conditioned avoidance and apomorphine-induced stereotypy, whereas in such tests as traction, potentiation of barbiturates, hypothermia and apomorphine induced vomiting, the antagonistic activity was nil. They concluded that anticholinergics showed a tendency to antagonize selectively the effects related to the extrapyramidal symptoms. Leslie and Maxwell (18) found that benztropine and scopolamine inhibited the anti-amphetamine effect as well as the cataleptic effect of thioproperazine and suggested that the clinical use of these anticholinergics might decrease the psychiatric effectiveness of the neuroleptic because the anti-amphetamine effect might be related to the clinical psychiatric effects.
However, it is dangerous to draw a hasty conclusion from these results with respect to the correlation between pharmacological and clinical effects. Virtually, many components which are related, more or less, to the antipsychotic effects and also to the extrapyramidal side-effects, may be involved in any pharmacological effect of neuroleptics. In addition, the possibility may exist that each neuroleptic exhibits a pharmacological effect through a different mechanism. Certainly, the component related to extrapyramidal symptoms in the pharmacological effects of neuroleptics may be removed by anticholinergics which clinically alleviate such side-effects. If so, the degree of antagonism by the anticholinergic will vary according to the rate that such a component is involved in each pharmacological effect. We assumed when designing this study that the degree of antagonism by the anti cholinergic might reflect the correlation between the pharmacological effects of neuroleptics and extrapyramidal symptoms. In the present study, the anticholinergic, biperiden, was capable of reducing, in most of neuroleptics, the cataleptic effect which was considered to be related to the extrapyramidal symptoms (1) (2) (3) (4) (5) . The antiavoidance effect of some drugs was also antagonized. However, the ptotic effect which was suggested to be related to sedation (8, 28) 
